1. Home
  2. SMG vs NAMS Comparison

SMG vs NAMS Comparison

Compare SMG & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scotts Miracle-Gro Company (The)

SMG

Scotts Miracle-Gro Company (The)

HOLD

Current Price

$62.56

Market Cap

3.5B

Sector

Industrials

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$33.93

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SMG
NAMS
Founded
1868
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
3.5B
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
SMG
NAMS
Price
$62.56
$33.93
Analyst Decision
Buy
Strong Buy
Analyst Count
6
8
Target Price
$73.00
$46.75
AVG Volume (30 Days)
913.3K
811.1K
Earning Date
04-29-2026
05-07-2026
Dividend Yield
4.26%
N/A
EPS Growth
504.92
N/A
EPS
N/A
N/A
Revenue
$3,016,500,000.00
N/A
Revenue This Year
N/A
$17.96
Revenue Next Year
$2.63
$540.65
P/E Ratio
N/A
N/A
Revenue Growth
6.17
N/A
52 Week Low
$45.61
$15.82
52 Week High
$72.35
$42.00

Technical Indicators

Market Signals
Indicator
SMG
NAMS
Relative Strength Index (RSI) 48.24 55.01
Support Level $58.68 $29.73
Resistance Level $64.96 $37.43
Average True Range (ATR) 2.58 1.77
MACD 0.05 0.38
Stochastic Oscillator 50.14 64.34

Price Performance

Historical Comparison
SMG
NAMS

About SMG Scotts Miracle-Gro Company (The)

Scotts Miracle-Gro is the largest purveyor of home lawn and gardening products in the US. The company sells a broad range of lawncare products, including grass seed, fertilizer, and lawn-related weed, animal, and disease control. US consumer typically generates the vast majority of companywide revenue and profits. Its lawncare and gardening products are well-recognized brands in the US, including Scotts, Miracle-Gro, Roundup, Ortho, and Tomcat.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: